Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497757 | 0.87 | KMT2A (0.54) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1824389 | 0.86 | KMT2A (0.53) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1812611 | 0.85 | KMT2A (0.50) | KMT2AMEN1ALDH1A1MAPK10MAPT | |
| SCHEMBL1813971 | 0.83 | KMT2A (0.46) | KMT2AMEN1ALDH1A1MAPK10MAPT | |
| SCHEMBL1813003 | 0.81 | MEN1 (0.46) | KMT2AMEN1ALDH1A1MAPK10MAPT | |
| SCHEMBL1819735 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1824465 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1819496 | 0.78 | MEN1 (0.44) | KMT2AMEN1ALDH1A1MAPTBRAF | |
| SCHEMBL1829076 | 0.78 | MEN1 (0.52) | KMT2AMEN1ALDH1A1MAPTBRAF | |
| SCHEMBL1812890 | 0.77 | MEN1 (0.48) | KMT2AMEN1ALDH1A1MAPK10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | KMT2A 676/4885MEN1 3469/4885ALDH1A1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.